Advertisement

Current Pain and Headache Reports

, Volume 12, Issue 1, pp 56–61 | Cite as

Obesity and chronic daily headache

  • Marcelo E. Bigal
  • Richard B. Lipton
Article

Abstract

Population studies suggest that obesity is associated with migraine progression from episodic to chronic daily headaches. Although not a risk factor for episodic migraine, obesity is associated with frequent and severe headaches among migraineurs. We suggest that obesity is an exacerbating factor for migraine. This association seems to be specific to migraine and does not apply to tension-type headache. We review the clinical evidence that links obesity and migraine progression. We then review the potential pathophysiologic mechanisms to support this relationship. We close by briefly discussing clinical interventions related to obesity and migraine.

Keywords

Obesity Migraine Migraine Attack Chronic Migraine Vasoactive Intestinal Polypeptide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Leonardi M, Steiner TJ, Scher AT, Lipton RB: The global burden of migraine: measuring disability in headache disorders with WHO’s Classification of Functioning, Disability, and Health (ICF). J Headache Pain 2005, 6:429–440.PubMedCrossRefGoogle Scholar
  2. 2.
    Lipton RB, Bigal ME, Diamond M, et al.: Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007, 68:343–349.PubMedCrossRefGoogle Scholar
  3. 3.
    Linet MS, Stewart WF: Migraine headache: epidemiologic perspectives. Epidemiol Rev 1984, 6:107–139.PubMedGoogle Scholar
  4. 4.
    Scher AI, Stewart WF, Lipton RB: Prevalence of frequent headache in a population sample. Headache 1998, 38:497–506.PubMedCrossRefGoogle Scholar
  5. 5.
    Lipton RB, Bigal ME: Migraine: epidemiology, impact, and risk factors for progression. Headache 2005, 45(Suppl 1):S3–S13.PubMedCrossRefGoogle Scholar
  6. 6.
    Mathew NT, Reuveni U, Perez F: Transformed or evolutive migraine. Headache 1987, 27:102–106.PubMedCrossRefGoogle Scholar
  7. 7.
    Silberstein SD, Lipton RB, Sliwinski M: Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology 1996, 47:871–875.PubMedGoogle Scholar
  8. 8.
    Kruit MC, van Buchem MA, Hofman PA, et al.: Migraine as a risk factor for subclinical brain lesions. JAMA 2004, 291:427–434.PubMedCrossRefGoogle Scholar
  9. 9.
    Kurth T, Gaziano JM, Cook NR, et al.: Migraine and risk of cardiovascular disease in women. JAMA 2006, 296:283–291.PubMedCrossRefGoogle Scholar
  10. 10.
    Welch KMA, Nagesh V, Aurora SK, Gelman N: Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache 2001, 41:629–637.PubMedCrossRefGoogle Scholar
  11. 11.
    Gursoy-Ozdemir Y, Qiu J, Matsuoka N, et al.: Cortical spreading depression activates and upregulates MMP-9. J Clin Invest 2004, 113:1447–1455.PubMedCrossRefGoogle Scholar
  12. 12.
    National Health and Nutrition Examination Survey, 2004. Available at http://www.cdc.gov/nchs/nhanes.htm. Accessed April 01, 2007.
  13. 13.
    Scher AI, Stewart WF, Ricci JA, Lipton RB: Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 2003, 106:81–88.PubMedCrossRefGoogle Scholar
  14. 14.
    Bigal ME, Liberman JN, Lipton RB: Obesity and migraine: a population study. Neurology 2006, 66:545–550.PubMedCrossRefGoogle Scholar
  15. 15.
    Bigal ME, Lipton RB: Obesity is a risk factor for transformed migraine but not for chronic tension-type headache. Neurology 2006, 67:252–257.PubMedCrossRefGoogle Scholar
  16. 16.
    Bigal ME, Tsang A, Loder E, et al.: Body mass index and primary headaches. The AMPP study. Arch Intern Med 2007, 167:1964–1970.PubMedCrossRefGoogle Scholar
  17. 17.
    Galuska DA, Serdula M, Pamuk E, et al.: Trends in overweight among US adults from 1987 to 1993: a multistate telephone survey. Am J Public Health 1996, 86:1729–1735.PubMedCrossRefGoogle Scholar
  18. 18.
    Castillo J, Munoz P, Guitera V, Pascual J: Epidemiology of chronic daily headache in the general population. Headache 1999, 39:190–196.PubMedCrossRefGoogle Scholar
  19. 19.
    Moskowitz MA: Basic mechanisms in vascular headache. Neurol Clin 1990, 8:801–815.PubMedGoogle Scholar
  20. 20.
    Cutrer FM, Yu XJ, Ayata G, et al.: Effects of PNU-109,291, a selective 5-HT1D receptor agonist, on electrically induced dural plasma extravasation and capsaicin-evoked c-fos immunoreactivity within trigeminal nucleus caudalis. Neuropharmacology 1999, 38:1043–1053.PubMedCrossRefGoogle Scholar
  21. 21.
    Goadsby PJ, Edvinsson L: The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993, 33:48–56.PubMedCrossRefGoogle Scholar
  22. 22.
    Goadsby PJ, Macdonald GJ: Extracranial vasodilatation mediated by VIP (vasoactive intestinal polypeptide). Brain Res 1985, 329:285–288.PubMedCrossRefGoogle Scholar
  23. 23.
    Sarchielli P, Alberti A, Baldi A, et al.: Proinflammatory cytokines, adhesion molecules, and lymphocyte integrin expression in the internal jugular blood of migraine patients without aura assessed ictally. Headache 2006, 46:200–207.PubMedCrossRefGoogle Scholar
  24. 24.
    Welch KM, Brandes AW, Salerno L, Brandes JL: C-reactive protein may be increased in migraine patients who present with complex clinical features. Headache 2006, 46:197–199.PubMedCrossRefGoogle Scholar
  25. 25.
    D’Amico D, Moschiano F, Leone M, et al.: Genetic abnormalities of the protein C system: shared risk factors in young adults with migraine with aura and with ischemic stroke? Cephalalgia 1998, 18:618–621.PubMedCrossRefGoogle Scholar
  26. 26.
    Flier JS: The adipocyte: storage depot or node on the energy information superhighway? Cell 1995, 80:15–18.PubMedCrossRefGoogle Scholar
  27. 27.
    Mohamed-Ali V, Pinkney JH, Coppack SW: Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 1998, 22:1145–1158.PubMedCrossRefGoogle Scholar
  28. 28.
    Herishanu Y, Rogowski O, Polliack A, Marilus R: Leukocytosis in obese individuals: possible link in patients with unexplained persistent neutrophilia. Eur J Haematol 2006, 76:516–520.PubMedCrossRefGoogle Scholar
  29. 29.
    Curat CA, Wegner V, Sengenes C, et al.: Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006, 49:744–747.PubMedCrossRefGoogle Scholar
  30. 30.
    Gram DX, Hansen AJ, Wilken M, et al.: Plasma calcitonin gene-related peptide is increased prior to obesity, and sensory nerve desensitization by capsaicin improves oral glucose tolerance in obese Zucker rats. Eur J Endocrinol 2005, 153:963–969.PubMedCrossRefGoogle Scholar
  31. 31.
    Siegel JM: Hypocretin (orexin): role in normal behavior and neuropathology. Annu Rev Psychol 2004, 55:25–48.CrossRefGoogle Scholar
  32. 32.
    Baranowska B, Wolinska-Witort E, Martynska M, et al.: Plasma orexin A, orexin B, leptin, neuropeptide Y (NPY) and insulin in obese women. Neuro Endocrinol Lett 2005, 26:714.Google Scholar
  33. 33.
    Kajiyama S, Kawamoto M, Shiraishi S: Spinal orexin-1 receptors mediate anti-hyperalgesic effects of intrathecally administered orexins in diabetic neuropathic pain model rats. Brain Res 2005, 1044:76–86.PubMedCrossRefGoogle Scholar
  34. 34.
    Matsuzawa Y: The metabolic syndrome and adipocytokines. FEBS Lett 2006, 580:2917–2921.PubMedCrossRefGoogle Scholar
  35. 35.
    Bigal ME, Lipton RB, Holland PR, Goadsby PJ: Obesity, migraine, and chronic migraine: possible mechanisms of interaction. Neurology 2007, 68:1851–1861.PubMedCrossRefGoogle Scholar
  36. 36.
    VanItallie TB, Yang MU: Current concepts in nutrition: diets and weight loss. N Engl J Med 1977, 297:1158–1161.CrossRefGoogle Scholar
  37. 37.
    Yang M, VanItallie TB: Effect of energy restriction on body composition and nitrogen balance in obese individuals. In Treatment of the Seriously Obese Patient. Edited by Wadden TA, VanItallie TB. New York: Guilford Press; 1992:83–106.Google Scholar
  38. 38.
    Stefanick ML, Mackey S, Sheehan M, et al.: Effects of the NCEP Step 2 diet and exercise on lipoprotein in postmenopausal women and men with low HDL-cholesterol and high LDL-cholesterol. N Engl J Med 1998, 339:12–20.PubMedCrossRefGoogle Scholar
  39. 39.
    NIH Consensus Conference. Physical Activity and Cardiovascular Health. JAMA 1996, 276:241–246.Google Scholar
  40. 40.
    Sidhaye A, Cheskin LJ: Pharmacologic treatment of obesity. Adv Psychosom Med 2006, 27:42–52.PubMedGoogle Scholar
  41. 41.
    Silberstein SD: Topiramate in migraine prevention. Headache 2005, 45(Suppl 1):S57–S65.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  1. 1.Department of NeurologyAlbert Einstein College of MedicineBronxUSA

Personalised recommendations